ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Haematology · J Thromb Haemost · 2026-05-27

ISTH-SSC expert consensus guidance on standardising platelet activation assays (serotonin release, HIPA, aggregation, flow cytometry, multielectrode aggregometry) for diagnosing heparin-induced thrombocytopenia, covering sampling, donors, heparin doses and interpretation.

Guideline
Althaus et al. Standardization of Platelet Activation Tests for the Diagnosis of Heparin-Induced Thrombocytopenia: Communication from the ISTH-SSC Subcommittee on Immune-Mediated Platelet Disorders
Haematology · J Thromb Haemost · 2026-03-25

In 1255 critically ill adults with COVID-19, intermediate-dose heparin did not improve organ support-free days vs standard low-dose thromboprophylaxis (OR 1.06; probability of benefit 73.5%). Survival 77.1% vs 76.7%; major bleeding 1.7% vs 2.1%.

RCTn = 1,255
Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia (REMAP-CAP) Investigators et al. Intermediate dose heparin thromboprophylaxis among critically ill patients with COVID-19: a randomized clinical trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.